Boceprevir and personalized medicine in hepatitis C virus infection

Pharmacogenomics and Personalized Medicine

Volumn 5, Issue 1, 2012, Pages 125-137

  Habersetzer, François ^a,b,c   Leboeuf, Céline ^b,c   Doffoël, Michel ^a,b,c   Baumert, Thomas F ^a,b,c  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c INSERM   (France)

Author keywords

Antiviral therapy; Boceprevir; Hepatitis C virus

Indexed keywords

ALPHA INTERFERON; ATORVASTATIN; BOCEPREVIR; CILUPREVIR; CYCLOSPORIN A; DEXAMETHASONE; DROSPIRENONE; EFAVIRENZ; ERYTHROPOIETIN; ESCITALOPRAM; KETOCONAZOLE; METHADONE; MIDAZOLAM; PEGINTERFERON ALPHA; PIMOZIDE; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; RIBAVIRIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; TACROLIMUS; TELAPREVIR; TRAZODONE;

ANEMIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CARDIOTOXICITY; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPNEA; FAINTNESS; FLU LIKE SYNDROME; FOOD; FOOD DRUG INTERACTION; GENE; HEART ARRHYTHMIA; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INOSINE TRIPHOSPHATASE GENE; INTERLEUKIN 28B GENE; LIVER CIRRHOSIS; LOW DRUG DOSE; MEDICAL HISTORY; MONOTHERAPY; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPHIL COUNT; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; RESPIRATION DEPRESSION; REVIEW; RHABDOMYOLYSIS; SEDATION; SIDE EFFECT; SURVIVAL;

EID: 84867489321     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S24259     Document Type: Review

References (63)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359-362.
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001; 345:41-52.
3. World Health Organization. Hepatitis C. Fact sheet N°164. July 2012. [Webpage on the Internet] http://www.who.int/mediacentre/factsheets/fs164/en/index.html. Accessed April 14, 2012.
4. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.
5. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007;5:453-463.
6. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35-S46.
7. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-1374.
8. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;315:1575-1578.
9. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517-524.
10. Imai Y, Kasahara A, Tanaka H, et al. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. J Gastroenterol. 2004;39:1069-1077.
11. Kasahara A, Tanaka H, Okanoue T, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat. 2004;11:148-156.
12. Katze MG, He Y, Gale M Jr. Viruses and interferon: a fight for supremacy. Nat Rev Immunol. 2002;2:675-687.
13. Pawlotsky JM. Therapy of hepatitis C: From empiricism to eradication. Hepatology. 2006;43 Suppl 1:S207-S220.
14. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet. 1991;337:1058-1061.
15. Di Bisceglie AM, Shindo M, Fong TL, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology. 1992;16:649-654.
16. Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology. 1994;107:812-817.
17. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426-1432.
18. Lohmann V, Körner F, Koch J, Herian U, Theilmann I, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285:110-113.
19. Lindenbach BD, Rice CM. Flaviviridae: The viruses and their replication. In: Fields Virology. Volume 1. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
20. Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell. 1996;87:343-355.
21. Love RA, Parge HE, Wickersham JA, et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell. 1996;87:331-342.
22. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 2003;426:186-189.
23. Malcolm BA, Liu R, Lahser F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother. 2006;50:1013-1020.
24. Merck. Victrelis (boceprevir) prescribing information. May 2011. Available at: http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf. Accessed July 10, 2012.
25. FDA US Food and Drug Administration. Drug approval package. Victrelis (boceprevir). Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202258Orig1s000TOC.cfm. Accessed December 14, 2011.
26. Ghosal A, Yuan Y, Tong W, et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos. 2011;39:510-521.
27. Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med. 2002;162:405-412.
28. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012;55:1620-1628.
29. Zeuzem S, Sarrazin C, Rouzier R, et al. Antiviral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-IFN-alpha). Hepatology. 2005;42 Suppl 1:S233-S234.
30. Susser S, Welker MW, Zettler M, et al. Clonal analysis of mutations selected in the HCV NS3 protease domain of genotype 1 non-responders treated with boceprevir (SCH503034). J Hepatol. 2008;48 Suppl 2:S29.
31. Flint M, Mullen S, Deatly AM, et al. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Antimicrob Agents Chemother. 2009;53:401-411.
32. Pawlotsky JM. Treatment of hepatitis C: don't put all your eggs in one basket! Gastroenterology. 2007;132:1611-1615.
33. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology. 2007;132:1270-1278.
34. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705-716.
35. Schiff E, Poordad F, Jacobson I, et al. Boceprevir (B) combination therapy in null responders (NR): response dependent on interferon responsiveness. J Hepatol. 2008;48 Suppl 2:S46.
36. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.
37. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364: 1207-1217.
38. Brass C, Barnard RJO, Howe JA, et al. Sustained virologic response and boceprevir resistance-associated variants observed in patients infected with HCV genotype 1a/1b when treated with boceprevir plus peginterferon alfa-2b/ribavirin. J Hepatol. 2011;54 Suppl 1:S471-S472.
39. Bronowicki JP, Davis M, Flamm S, et al. Sustained virologic response (SVR) in prior peginterferon/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC)-+-PR: the provide study interim results. J Hepatol. 2012;56 Suppl 2:S6.
40. Vierling JM, Ralston R, Lawitz EJ, et al. Long-term outcomes following combination treatment with boceprevir plus peg-intron/ribavirin (P/R) in patients with chronic hepatitis C, genotype 1 (CHC-G1). J Hepatol. 2010;52 Suppl 1:S470-S471.
41. Jacobson IM, Marcellin P, Zeuzem S, et al. Refinement of stopping rules during treatment of hepatitis C genotype 1infection with boceprevir combined with peginterferon/ribavirin. Hepatology. May 22, 2012. [Epub ahead of print.]
42. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470-477.
43. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461: 399-401.
44. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461: 798-801.
45. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120-129.
46. Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. May 21, 2012. [Epub ahead of print.]
47. Kwo PY. Phase III results in genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. Liver Int. 2012;32 Suppl 1:S39-S43.
48. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347: 975-982.
49. Fellay J, Thompson A, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464: 405-408.
50. Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. 2010;139:1181-1189.
51. Poordad F, Lawitz EJ, Reddy KR, et al. A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin. J Hepatol. 2012;56 Suppl 2:S559.
52. Golden-Mason L, Klarquist J, Wahed AS, Rosen HR. Cutting edge: Programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol. 2008;180:3637-3641.
53. Urbani S, Amadei B, Tola D, et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol. 2006;80:11398-11403.
54. Vidal-Castiñeira JR, López-Vázquez A, Alonso-Arias R, et al. A predictive model of treatment outcome in patients with chronic HCV infection using IL28B and PD-1 genotyping. J Hepatol. 2012;56: 1230-1238.
55. Sulkowski M, Pol S, Cooper C, et al. Boceprevir+ pegylated interferon + ribavirin for the treatment of HCV/HIV-coinfected patients: end of treatment (week 48) interim results. Abstract 47 presented at the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA; March 5-8, 2012.
56. Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther. 2012;35:647-662.
57. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology. 2006;43:54-63.
58. Lawitz E, Poordad F, Kowdley KV, et al. A 12-week interferon-free regimen of ABT-450/R, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% of treatment-naive HCV IL28B-CC genotype-1-infected subjects. J Hepatol. 2012;56 Suppl 2:S7.
59. Sulkowski M, Rodriguez-Torres M, Lawitz E, et al. High SVR rate in treatment-naïve HCV genotype 1a and 1b patients treated for 12 weeks with an interferon-free all-oral quad regimen: interim results. J Hepatol. 2012;56 Suppl 2:S559.
60. Approval of Victrelis (boceprevir) by US Food and Drug Administration. May 2011. Available at: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm255413.htm. Accessed July 10, 2012.
61. Barritt AS, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology. 2012;14: 1314-1323.
62. Klibanov OM, Vickery SB, Olin JL, et al. Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C. Pharmacotherapy. 2012;32:173-190.
63. Hulkotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology. May 11, 2012. [Epub ahead of print.]